ASCO Genitourinary Symposium

An analysis found docetaxel plus ADT to be the most cost-effective therapy for HRR+ metastatic hormone-sensitive prostate cancer.

RAMPART shows early quality-of-life declines with adjuvant Imfinzi and Imjudo, improving over time, though later cognitive and pain effects emerge.

Phase 2 INDIBLADE data support Yervoy and Opdivo before bladder-sparing chemoradiotherapy.

Keytruda/Welireg and Welireg/Lenvima combinations show improved survival and disease control in kidney cancer, according to new data from ASCO GU.

Keytruda plus Welireg lowered the risk of recurrence in high-risk clear cell kidney cancer after surgery.

Welireg plus Lenvima improved outcomes compared with versus Cabometyx in advanced clear cell renal cell carcinoma after immunotherapy.

Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials.

Disitamab vedotin demonstrated responses in previously treated HER2-expressing advanced urothelial carcinoma, with activity across HER2 expression levels.

Adding cabazitaxel to hormone therapy and radiation did not improve survival and caused more side effects in high-risk localized prostate cancer.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase 3 genitourinary cancer trials.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.